A Case of Ketoacidosis Caused by Tirzepatide in Non-diabetic Individual
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: A new agonist for the glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor is trizepatide. It was just approved to help non-diabetic persons lose weight and treat their diabetes. Case description: Due to the potential for starving ketoacidosis and insulin resistance, we report case of ketoacidosis following administration of trizepatide in an obese non-diabetic patient. Conclusion: Trizepatide, a dual-acting GLP-1 and GIP receptor agonist, can cause ketoacidosis in patients who are obese but not diabetic.
Fields of Study & Subjects
Diabetes Treatment and Management
Pharmacology and Obesity Treatment
Diet and metabolism studies
Publication details
- Journal / source
- International Journal of Innovative Research in Medical Science
- Volume
- 11
- Issue
- 03
- Pages
- 102–104
- Publication date
- 1 January 2026
- Language
- EN